TY - JOUR T1 - Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. JO - Health Technol Assess PY - 2012/10/01 AU - Papaioannou D AU - Rafia R AU - Rathbone J AU - Stevenson M AU - Buckley Woods H AU - Stevens J ED - DO - DOI: 10.3310/hta16370 VL - 16 IS - 37 SP - 1 EP - iv Y2 - 2025/10/03 ER -